About Epizyme, Inc.Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.EPIZYME, INC. CONSOLIDATED BALANCE SHEET DATA (UNAUDITED)(Amounts in thousands)September 30,December 31,20132012Cash and cash equivalents
50,70669,445Redeemable convertible preferred stock (Series A, B and C)
-76,156Stockholders' equity (deficit)
87,283(51,126)EPIZYME, INC.CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)(Amounts in thousands except per share data)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012Collaboration revenue
36,327Operating expenses:Research and development
14,5849,25841,88227,385General and administrative
3,5871,6309,6645,175Total operating expenses
18,17110,88851,54632,560(Loss) income from operations
(9,727)4,443(19,381)3,767Other income (expense), net
235(32)69Net (loss) income
|SOURCE Epizyme, Inc.|
Copyright©2012 PR Newswire.
All rights reserved